BLAINJECTIONINJECTABLE
Approved
Jan 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
89
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications (13)
more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)giant cell arteritis (GCA) in adult patientsactive polyarticular juvenile idiopathic arthritis in patients 2 years of ageolderactive systemic juvenile idiopathic arthritis in patients 2 years of agechimeric antigen receptor (CAR) T cell-induced severelife-threatening cytokine release syndrome in adultscoronavirus disease 2019 (COVID-19) in hospitalized adultrequire supplemental oxygennon-invasiveinvasive mechanical ventilationextracorporeal membrane oxygenation (ECMO)Rheumatoid Arthritis
Clinical Trials (5)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Started Dec 2025
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Started May 2025
20 enrolled
Multiple Myeloma
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Started Jul 2024
168 enrolled
Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer
Real World Use of Tocilizumab Biosimilar studY
Started Mar 2024
600 enrolled
Rheumatoid Arthritis
A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
Started Jan 2024
300 enrolled
Healthy Volunteer